Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Income from Continuing Operations (2016 - 2025)

Rein Therapeutics filings provide 10 years of Income from Continuing Operations readings, the most recent being 7356000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 16.6% year-over-year to 7356000.0, compared with a TTM value of 10616000.0 through Dec 2025, up 21.33%, and an annual FY2025 reading of 9904000.0, up 26.61% over the prior year.
  • Income from Continuing Operations hit 7356000.0 in Q4 2025 for Rein Therapeutics, up from 5492000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 8820000.0 in Q4 2024, with the low at 9039000.0 in Q2 2024.
  • Median Income from Continuing Operations over the past 5 years was 6221500.0 (2022), compared with a mean of 4704150.0.
  • The largest YoY upside for Income from Continuing Operations was 220.99% in 2024 against a maximum downside of 380.8% in 2024.
  • Year by year, Income from Continuing Operations stood at 6816000.0 in 2021, then soared by 31.0% to 4703000.0 in 2022, then crashed by 55.01% to 7290000.0 in 2023, then skyrocketed by 220.99% to 8820000.0 in 2024, then dropped by 16.6% to 7356000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 7356000.0, 5492000.0, and 6871000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.